- Home
- SCLX vs MGLD Comparison
SCLX vs MGLD Comparison
Compare SCLX & MGLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- MGLD
- Stock Information
- Founded
- SCLX 2011
- MGLD 1996
- Country
- SCLX United States
- MGLD United States
- Employees
- SCLX N/A
- MGLD N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- MGLD Finance/Investors Services
- Sector
- SCLX Health Care
- MGLD Finance
- Exchange
- SCLX Nasdaq
- MGLD Nasdaq
- Market Cap
- SCLX 35.7M
- MGLD 35.3M
- IPO Year
- SCLX N/A
- MGLD N/A
- Fundamental
- Price
- SCLX $18.87
- MGLD $0.89
- Analyst Decision
- SCLX Strong Buy
- MGLD
- Analyst Count
- SCLX 3
- MGLD 0
- Target Price
- SCLX $367.50
- MGLD N/A
- AVG Volume (30 Days)
- SCLX 324.6K
- MGLD 10.7K
- Earning Date
- SCLX 08-13-2025
- MGLD 09-17-2025
- Dividend Yield
- SCLX N/A
- MGLD N/A
- EPS Growth
- SCLX N/A
- MGLD N/A
- EPS
- SCLX N/A
- MGLD N/A
- Revenue
- SCLX $44,236,000.00
- MGLD $31,205,000.00
- Revenue This Year
- SCLX $89.26
- MGLD N/A
- Revenue Next Year
- SCLX $203.95
- MGLD N/A
- P/E Ratio
- SCLX N/A
- MGLD N/A
- Revenue Growth
- SCLX N/A
- MGLD N/A
- 52 Week Low
- SCLX $3.60
- MGLD $0.64
- 52 Week High
- SCLX $45.15
- MGLD $2.10
- Technical
- Relative Strength Index (RSI)
- SCLX 63.34
- MGLD 58.70
- Support Level
- SCLX $15.61
- MGLD $0.67
- Resistance Level
- SCLX $22.01
- MGLD $0.79
- Average True Range (ATR)
- SCLX 2.21
- MGLD 0.08
- MACD
- SCLX -0.14
- MGLD 0.01
- Stochastic Oscillator
- SCLX 62.35
- MGLD 100.00
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.